Skip to main content

Search form

Medicines for Malaria Venture

Developing antimalarials to save lives

  • Research & Development
    • MMV-supported projects
    • R&D areas of work
      • Next-generation medicines
      • Science of eradication
      • Products for vulnerable populations
    • Working with regulators
    • Information for scientists
      • Call for proposals
      • TPPs & TCPs
    • Project of the year award
    • Computational chemistry
      • Global health compound design webinars
    • R&D challenges
  • Access
    • Products & projects
    • Areas of work
      • Supporting introduction
      • Enhancing reach
      • Informing R&D
      • Gathering market intelligence
    • Product maps
      • ASAQ Winthrop® map
      • ASMQ map
      • Artesun® map
      • Coartem® Dispersible map
      • Eurartesim® map
      • Kozenis/Krintafel map
      • Pyramax® map
      • Pyramax® granules map
      • Rectal artesunate map
      • SPAQ map
    • Tool Kits
      • Injectable artesunate tool kit
      • Rectal artesunate tool kit
      • Seasonal Malaria Chemoprevention Tool Kit
    • The road to health impact
    • Access challenges
  • Partnering
    • Our partner network
    • The PDP model
    • Socially responsible agreements
    • Our clinical centre partners
    • Our donors
      • Current donors
      • Past donors
      • Donate to MMV
      • Donor stories
  • Our impact
    • Achievements
    • Real life stories
    • Impact of the global malaria community
  • About us
    • What we do
      • An overview of our work
      • Our strategic focus
      • Our history
    • People & governance
      • Staff bios
      • Staff map
      • Staff interviews
      • Board of Directors
      • MMV North America Board
      • Expert Scientific Advisory Committee
      • Access & Product Management Advisory Committee
      • Global Safety Board
    • Work with us
      • Jobs
      • RFPs/RFIs
      • MMV's internship programme
    • Policies
    • Funding and expenditure
    • FAQs
    • Contact us
  • Malaria & medicines
    • Definitions and symptoms
    • Five species
    • Parasite lifecycle
    • Malaria facts & figures
    • Malaria treatment
    • History of antimalarials
    • Optimizing artemisinin production
    • Malaria online course
  • Newsroom
    • News & Press Releases
    • Films
    • Infographics
    • Interviews
    • Image slideshows
    • Publications
    • Audio
    • Events
  • MMV Open
    • Pandemic Response Box
      • About the Pandemic Response Box
      • Request the Pandemic Response Box
      • Supporting information
      • Terms & conditions
    • Pathogen Box
      • About the Pathogen Box
      • Request the Pathogen Box
      • Exploiting the Pathogen Box
      • Pathogen Box research
      • Supporting information
      • Terms & conditions
    • Malaria Box
      • About the Malaria Box
      • Malaria Box Research
      • Supporting information
      • Terms & conditions
    • Map of box orders
    • Follow-up guidelines
    • Open Source Drug Discovery
    • MMV Open Team
    • Contact us
  • Home
  • Our impact
  • Achievements

Achievements

First single-dose medicine to prevent the relapse of P. vivax approved by US FDA

Two rectal artesunate suppository products for pre-referral management of severe malaria approved

68 million courses of seasonal malaria chemoprevention delivered to countries in the Sahel in 2017

350 million treatments of Coartem® Dispersible delivered to over 50 countries

Pyramax® Granules added to the WHO's Model List of Essential Medicines for Children

100 million vials of Artesun® delivered to treat children with severe malaria

CANTAM study initiated

14 compounds in preclinical and clinical development

150 active partners in MMV's network, working to help defeat malaria

Over 230 Pathogen Boxes shipped

>90% of severe malaria cases now treated with injectable artesunate in preference to quinine

18,000 health-care workers trained to administer injectable artesunate for severe malaria

USD 1 = USD 3.5 of investment impact thanks to direct and in-kind support from partners

19 new malaria drug targets validated since 1999

MMV wins Open Data Innovation Award for work on the Malaria Box

Dr David Reddy, CEO, MMV and Dr Bernard Pécoul, CEO, DNDi

2 ACTs developed by DNDi and partners transitioned to MMV

More than 200,000 doses of Eurartesim® distributed in two ground-breaking mass drug administration pilots

Key landmarks for MMV-supported medicines

Key Achievements over MMV's first 15 years

  • RSS subscribe
    Printer friendly

Follow us

  • Facebook
  • LinkedIn
  • Twitter
  • GooglePlus
  • YouTube

Subscribe

Previous newsletters

Contact us

  • Tel: +41 22 555 03 00
    • Message us
    • Office directions
© MMV 2019
Website by Manta Ray Media
  • Glossary
  • Disclaimer
  • Privacy
  • Sitemap